|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
[gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of CASP7 protein; [gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of PARP1 protein; Acetylcysteine affects the reaction [[gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of CASP7 protein]; Acetylcysteine affects the reaction [[gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of PARP1 protein]; gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin] |
CTD |
PMID:25824409 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
affects localization |
ISO |
gambogic acid affects the localization of AIFM1 protein |
CTD |
PMID:19464570 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases activity decreases expression |
ISO |
gambogic acid results in decreased activity of AKT1 protein gambogic acid results in decreased expression of AKT1 mRNA |
CTD |
PMID:19433130 PMID:33533530 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
decreases expression |
ISO |
gambogic acid results in decreased expression of AKT2 mRNA |
CTD |
PMID:33533530 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
gambogic acid results in increased expression of BAX mRNA |
CTD |
PMID:15968715 PMID:33533530 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression multiple interactions decreases expression |
ISO |
gambogic acid affects the expression of BCL2 protein [Verapamil co-treated with gambogic acid] results in decreased expression of BCL2 protein; Fluorouracil promotes the reaction [gambogic acid results in decreased expression of BCL2 mRNA] |
CTD |
PMID:15968715 PMID:19084572 PMID:19433130 PMID:24373880 PMID:33533530 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions affects expression |
ISO |
[gambogic acid co-treated with Doxorubicin] affects the expression of BIRC5 protein; SB 203580 affects the reaction [[gambogic acid co-treated with Doxorubicin] affects the expression of BIRC5 protein] gambogic acid affects the expression of BIRC5 protein |
CTD |
PMID:25824409 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression |
ISO |
[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [Verapamil co-treated with gambogic acid] results in increased cleavage of and results in increased activity of CASP3 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; Fluorouracil promotes the reaction [gambogic acid results in decreased expression of CASP3 mRNA] |
CTD |
PMID:19084572 PMID:24291039 PMID:24373880 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
[gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of CASP7 protein; Acetylcysteine affects the reaction [[gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of CASP7 protein] |
CTD |
PMID:25824409 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [Verapamil co-treated with gambogic acid] results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:24291039 PMID:24373880 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
decreases expression multiple interactions |
ISO |
gambogic acid results in decreased expression of CASP9 protein alternative form [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [Verapamil co-treated with gambogic acid] results in increased cleavage of and results in increased activity of CASP9 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein] |
CTD |
PMID:19464570 PMID:24291039 PMID:24373880 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
[Verapamil co-treated with gambogic acid] results in increased expression of DDIT3 protein; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein] |
CTD |
PMID:24291039 PMID:24373880 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases activity |
ISO |
gambogic acid results in decreased activity of GSK3B protein |
CTD |
PMID:19433130 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
ISO |
Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein] |
CTD |
PMID:24291039 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Ncoa3 |
nuclear receptor coactivator 3 |
decreases expression |
ISO |
gambogic acid results in decreased expression of NCOA3 |
CTD |
PMID:19433130 |
|
NCBI chr 3:154,738,566...154,821,395
Ensembl chr 3:154,738,581...154,818,594
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage decreases expression multiple interactions |
ISO |
gambogic acid results in increased cleavage of PARP1 protein gambogic acid results in decreased expression of PARP1 mRNA [gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of PARP1 protein; [Verapamil co-treated with gambogic acid] results in increased cleavage of PARP1 protein; Acetylcysteine affects the reaction [[gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [[Verapamil co-treated with gambogic acid] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[Verapamil co-treated with gambogic acid] results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]; Fluorouracil promotes the reaction [gambogic acid results in decreased expression of PARP1 mRNA]; Fluorouracil promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]; gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein] |
CTD |
PMID:19084572 PMID:19464570 PMID:24291039 PMID:24373880 PMID:25824409 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases activity |
ISO |
gambogic acid results in decreased activity of RPS6KB1 protein |
CTD |
PMID:19433130 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Tyms |
thymidylate synthetase |
decreases expression multiple interactions |
ISO |
gambogic acid results in decreased expression of TYMS mRNA gambogic acid inhibits the reaction [Fluorouracil results in increased expression of TYMS mRNA] |
CTD |
PMID:19084572 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Umps |
uridine monophosphate synthetase |
multiple interactions increases expression |
ISO |
Fluorouracil promotes the reaction [gambogic acid results in increased expression of UMPS mRNA] |
CTD |
PMID:19084572 |
|
NCBI chr11:66,806,107...66,816,520
Ensembl chr11:66,806,045...66,821,903
|
|
G |
Wnt5a |
Wnt family member 5A |
decreases expression |
ISO |
gambogic acid results in decreased expression of WNT5A mRNA; gambogic acid results in decreased expression of WNT5A protein |
CTD |
PMID:33533530 |
|
NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234
|
|